The Supreme Court on Oct. 1 turned down an appeal by Pfizer Inc. aimed at preventing the sale of a generic version of its best-selling drug for high blood pressure.

The New York-based pharmaceutical giant had asked the court to overturn an appeals court ruling earlier this year, which determined that Pfizer’s Norvasc patent is invalid. The justices declined to hear Pfizer’s appeal.